Company intelligence / Profile preview
CPL Biologicals
Ahmedabad, Gujarat, India
- Ownership
- Private
- Employees
- ~53
- Development stage
- Other
01
Overview
CPL Biologicals has advanced a rabies vaccine to Phase 3, malaria vaccine to Phase 1 (now discontinued), and hepatitis E vaccine in preclinical. Its lead rabies vaccine employs recombinant and VLP modalities, with positive clinical results presented by partners for similar technologies.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccineGenetically engineered subunit vaccineRecombinant protein
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Cadila PharmaceuticalsNovavaxNational Institute of Allergy & Infectious Diseases (for Hepatitis E program)International Centre for Genetic Engineering and Biotechnology (ICGEB) (for malaria vaccine)
Beyond the preview
Go deeper on CPL Biologicals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPL Biologicals.